title: An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand.
abstract: Coinfection with HIV and hepatitis B virus (HBV) is common in resource-limited settings but is frequently not diagnosed. The authors retrospectively tested specimens for HBV in HIV-infected Thai women who had participated in an antiretroviral therapy (ART) clinical study. A substantial proportion (27 of 211; 13%) of HIV-infected women were HBV coinfected. Among HIV/HBV-coinfected women, the authors observed similar rates of antiretroviral-associated liver toxicity (despite nevirapine [NVP] use) and CD4 count reconstitution as observed in HIV-monoinfected women. Hepatitis B surface antigen (HBsAg) screening detected the majority (81%) of HBV coinfections, including all 5 HBV-coinfected women who did not suppress HBV despite 48 weeks of lamivudine (3TC)-containing ART and could be used to tailor ART for patients diagnosed with HBV coinfection in accordance with World Health Organization guidelines. Although HBsAg screening did not diagnose 5 occult HBV coinfections, these women achieved HBV suppression on 3TC-containing ART, suggesting that not detecting occult HBV coinfection would have limited clinical impact.
authors.affiliation: Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
authors.forename: Philip James
authors.initials: PJ
authors.lastname: Peters
authors.forename: Janet M
authors.initials: JM
authors.lastname: McNicholl
authors.forename: Boonyos
authors.initials: B
authors.lastname: Raengsakulrach
authors.forename: Punneeporn
authors.initials: P
authors.lastname: Wasinrapee
authors.forename: Famui
authors.initials: F
authors.lastname: Mueanpai
authors.forename: Winai
authors.initials: W
authors.lastname: Ratanasuwan
authors.forename: Poj
authors.initials: P
authors.lastname: Intalapaporn
authors.forename: Jan
authors.initials: J
authors.lastname: Drobeniuc
authors.forename: Sumathi
authors.initials: S
authors.lastname: Ramachandran
authors.forename: Hong
authors.initials: H
authors.lastname: Thai
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Xia
authors.forename: Saleem
authors.initials: S
authors.lastname: Kamili
authors.forename: Yury
authors.initials: Y
authors.lastname: Khudyakov
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Weidle
authors.forename: Chong Gee
authors.initials: CG
authors.lastname: Teo
authors.forename: Michelle S
authors.initials: MS
authors.lastname: McConnell
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D060085:Coinfection / Q000175:diagnosis* / Q000188:drug therapy / Q000821:virology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006509:Hepatitis B / Q000175:diagnosis* / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D012189:Retrospective Studies; D013785:Thailand; D019562:Viral Load / Q000187:drug effects
chemical_list: D044966:Anti-Retroviral Agents; D019259:Lamivudine
keywords: HIV; hepatitis B virus; lamivudine